Literature DB >> 25539124

Remission of recalcitrant dermatomyositis treated with ruxolitinib.

Thorsten Hornung1, Viktor Janzen, Franz-Josef Heidgen, Dominik Wolf, Thomas Bieber, Joerg Wenzel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25539124     DOI： 10.1056/NEJMc1412997

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  30 in total

Review 1.  Juvenile dermatomyositis: advances in clinical presentation, myositis-specific antibodies and treatment.

Authors:  Jian-Qiang Wu; Mei-Ping Lu; Ann M Reed
Journal:  World J Pediatr       Date:  2019-09-26       Impact factor: 2.764

Review 2.  [Familial chilblain lupus : Type 1 interferonopathy with model character].

Authors:  C Fiehn
Journal:  Z Rheumatol       Date:  2017-05       Impact factor: 1.372

Review 3.  Familial Chilblain Lupus - What Can We Learn from Type I Interferonopathies?

Authors:  Christoph Fiehn
Journal:  Curr Rheumatol Rep       Date:  2017-08-26       Impact factor: 4.592

Review 4.  The relationship between JAK2(V617F) mutation and dermatomyositis-a case report and literature review.

Authors:  Qin Xu; Xuexiao Jin; Yu Jiang; Xin Dang; Yongmei Han
Journal:  Clin Rheumatol       Date:  2020-07-16       Impact factor: 2.980

Review 5.  Recent Advances in Pharmacological Treatments of Adult Dermatomyositis.

Authors:  Kristen L Chen; Majid Zeidi; Victoria P Werth
Journal:  Curr Rheumatol Rep       Date:  2019-08-31       Impact factor: 4.592

Review 6.  JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.

Authors:  Daniella M Schwartz; Yuka Kanno; Alejandro Villarino; Michael Ward; Massimo Gadina; John J O'Shea
Journal:  Nat Rev Drug Discov       Date:  2017-11-06       Impact factor: 84.694

7.  JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.

Authors:  Daniella M Schwartz; Yuka Kanno; Alejandro Villarino; Michael Ward; Massimo Gadina; John J O'Shea
Journal:  Nat Rev Drug Discov       Date:  2017-12-28       Impact factor: 84.694

Review 8.  JAK inhibitors in dermatology: The promise of a new drug class.

Authors:  William Damsky; Brett A King
Journal:  J Am Acad Dermatol       Date:  2017-01-28       Impact factor: 11.527

Review 9.  [Dermatomyositis-update].

Authors:  B Volc-Platzer
Journal:  Hautarzt       Date:  2015-08       Impact factor: 0.751

Review 10.  Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases.

Authors:  Daniella M Schwartz; Michael Bonelli; Massimo Gadina; John J O'Shea
Journal:  Nat Rev Rheumatol       Date:  2015-12-03       Impact factor: 20.543
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.